Skip to main content
Top
Published in: Supportive Care in Cancer 9/2017

01-09-2017 | Original Article

Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis

Authors: A. R. T. Bergin, E. Hovey, A. Lloyd, G. Marx, P. Parente, T. Rapke, P. de Souza

Published in: Supportive Care in Cancer | Issue 9/2017

Login to get access

Abstract

Purpose

Fatigue is a prevalent and debilitating side effect of docetaxel chemotherapy in metastatic prostate cancer. A better understanding of the kinetics and nature of docetaxel-related fatigue may provide a framework for intervention.

Methods

This secondary analysis was performed using the MOTIF database, from a phase III, randomised, double-blind, placebo-controlled study of modafinil (200 mg/day for 15 days) for docetaxel-related fatigue in men with metastatic prostate cancer [1]. The pattern of fatigue was analysed using the MDASI (MD Anderson Symptom Inventory) score. The impact of modafinil, cumulative docetaxel exposure, age and smoking status on fatigue kinetics were explored. Fatigue-related symptoms were assessed using the SOMA6 (fatigue and related symptoms) subset of the SPHERE (Somatic and Psychological Health Report). Mood was tracked using the short form 36 health survey questionnaire (SF-36).

Results

Across four docetaxel cycles, fatigue scores were higher in the first week and decreased over weeks two and three. Whilst men randomised to modafinil had reduced fatigue scores, cumulative docetaxel had little impact. Younger men (55–68 years) had significantly reduced fatigue scores, whereas current and ex-smokers had higher scores. There was no significant change in mood status or haemoglobin across treatment cycles. Men described both ‘somnolence’ and ‘muscle fatigue’ contributing significantly to their symptom complex.

Conclusions

Assessment and management of docetaxel-related fatigue remains an important challenge. Given the complex, multifactorial nature of fatigue, identification through structured interview and interventions targeted to specific ‘at risk’ groups may be the most beneficial. Understanding the temporal pattern (kinetics) and nature of fatigue is critical to guide this process.
Literature
1.
go back to reference Hovey E, Souza P de, Marx G, et al (2014) Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer 22:1233–1242. doi: 10.1007/s00520-013-2076-0 Hovey E, Souza P de, Marx G, et al (2014) Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer 22:1233–1242. doi: 10.​1007/​s00520-013-2076-0
2.
go back to reference Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13–19PubMed Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13–19PubMed
3.
go back to reference Hofman M, Morrow GR, Roscoe JA et al (2004) Cancer patients’ expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938 patients from community practices. Cancer 101:851–857. doi:10.1002/cncr.20423 CrossRefPubMed Hofman M, Morrow GR, Roscoe JA et al (2004) Cancer patients’ expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938 patients from community practices. Cancer 101:851–857. doi:10.​1002/​cncr.​20423 CrossRefPubMed
4.
go back to reference Berger AM, Mooney K, Alvarez-Perez A et al (2015) Cancer-related fatigue, version 2.2015. J Natl Compr Cancer Netw 13:1012–1039CrossRef Berger AM, Mooney K, Alvarez-Perez A et al (2015) Cancer-related fatigue, version 2.2015. J Natl Compr Cancer Netw 13:1012–1039CrossRef
6.
go back to reference Jacobsen PB, Hann DM, Azzarello LM et al (1999) Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manag 18:233–242CrossRef Jacobsen PB, Hann DM, Azzarello LM et al (1999) Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manag 18:233–242CrossRef
7.
8.
go back to reference (2002) Chronic fatigue syndrome. Clinical practice guidelines--2002. Med J Aust 176 Suppl:S23–56 (2002) Chronic fatigue syndrome. Clinical practice guidelines--2002. Med J Aust 176 Suppl:S23–56
10.
go back to reference Hadzi-Pavlovic D, Hickie IB, Wilson AJ et al (2000) Screening for prolonged fatigue syndromes: validation of the SOFA scale. Soc Psychiatry Psychiatr Epidemiol 35:471–479CrossRefPubMed Hadzi-Pavlovic D, Hickie IB, Wilson AJ et al (2000) Screening for prolonged fatigue syndromes: validation of the SOFA scale. Soc Psychiatry Psychiatr Epidemiol 35:471–479CrossRefPubMed
11.
go back to reference Bennett BK, Goldstein D, Chen M et al (2014) Characterization of fatigue states in medicine and psychiatry by structured interview. Psychosom Med 76:379–388CrossRefPubMed Bennett BK, Goldstein D, Chen M et al (2014) Characterization of fatigue states in medicine and psychiatry by structured interview. Psychosom Med 76:379–388CrossRefPubMed
13.
go back to reference Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520. doi:10.1056/NEJMoa041318 CrossRefPubMed Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520. doi:10.​1056/​NEJMoa041318 CrossRefPubMed
14.
go back to reference Tannock IF, Wit R de, Berry WR, et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. doi: 10.1056/NEJMoa040720 Tannock IF, Wit R de, Berry WR, et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. doi: 10.​1056/​NEJMoa040720
15.
go back to reference James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177. doi:10.1016/S0140-6736(15)01037-5 CrossRefPubMedPubMedCentral James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177. doi:10.​1016/​S0140-6736(15)01037-5 CrossRefPubMedPubMedCentral
17.
go back to reference Al-Batran S-EE, Hozaeel W, Tauchert FK et al (2015) The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol 26:1244–1248. doi:10.1093/annonc/mdv129 CrossRefPubMed Al-Batran S-EE, Hozaeel W, Tauchert FK et al (2015) The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol 26:1244–1248. doi:10.​1093/​annonc/​mdv129 CrossRefPubMed
19.
go back to reference Awada A, Hendlisz A, Christensen O et al (2012) Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer 48:465–474. doi:10.1016/j.ejca.2011.12.026 CrossRefPubMed Awada A, Hendlisz A, Christensen O et al (2012) Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer 48:465–474. doi:10.​1016/​j.​ejca.​2011.​12.​026 CrossRefPubMed
21.
go back to reference Hickie IB, Davenport TA, Hadzi-Pavlovic D et al (2001) Development of a simple screening tool for common mental disorders in general practice. Med J Aust 175(Suppl):S10–S17PubMed Hickie IB, Davenport TA, Hadzi-Pavlovic D et al (2001) Development of a simple screening tool for common mental disorders in general practice. Med J Aust 175(Suppl):S10–S17PubMed
23.
25.
go back to reference Glaus A, Crow R, Hammond S (1996) A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 4:82–96CrossRefPubMed Glaus A, Crow R, Hammond S (1996) A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 4:82–96CrossRefPubMed
27.
go back to reference Cella D, Davis K, Breitbart W, Curt G (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385–3391CrossRefPubMed Cella D, Davis K, Breitbart W, Curt G (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385–3391CrossRefPubMed
31.
go back to reference Jones D, Zhao F, Fisch MJ et al (2014) The validity and utility of the MD Anderson symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 12:41–49. doi:10.1016/j.clgc.2013.07.003 CrossRefPubMed Jones D, Zhao F, Fisch MJ et al (2014) The validity and utility of the MD Anderson symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 12:41–49. doi:10.​1016/​j.​clgc.​2013.​07.​003 CrossRefPubMed
33.
go back to reference Yennurajalingam S, Frisbee-Hume S, Palmer JL et al (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076–3082. doi:10.1200/JCO.2012.44.4661 CrossRefPubMed Yennurajalingam S, Frisbee-Hume S, Palmer JL et al (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076–3082. doi:10.​1200/​JCO.​2012.​44.​4661 CrossRefPubMed
37.
38.
41.
go back to reference Bower JE, Ganz PA, Desmond KA et al (2000) Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743–753CrossRefPubMed Bower JE, Ganz PA, Desmond KA et al (2000) Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743–753CrossRefPubMed
Metadata
Title
Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis
Authors
A. R. T. Bergin
E. Hovey
A. Lloyd
G. Marx
P. Parente
T. Rapke
P. de Souza
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3706-8

Other articles of this Issue 9/2017

Supportive Care in Cancer 9/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine